Moderna (Germany) Top Insiders
0QF Stock | EUR 40.47 1.59 3.78% |
Moderna employs about 3.9 K people. The company is managed by 23 executives with a total tenure of roughly 117 years, averaging almost 5.0 years of service per executive, having 169.57 employees per reported executive. Examination of Moderna's management performance can provide insight into the company performance.
Stephane Bancel CEO Chief Executive Officer, Director |
Moderna |
Moderna Management Team Effectiveness
The company has return on total asset (ROA) of 0.233 % which means that it generated a profit of $0.233 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.5027 %, meaning that it generated $0.5027 on every $100 dollars invested by stockholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities.Moderna Workforce Comparison
Moderna is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 210,924. Moderna claims roughly 3,900 in number of employees contributing just under 2% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.43 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.49 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.49. Moderna Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Moderna Price Series Summation is a cross summation of Moderna price series and its benchmark/peer.
Moderna Notable Stakeholders
A Moderna stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moderna often face trade-offs trying to please all of them. Moderna's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moderna's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stephane Bancel | Chief Executive Officer, Director | Profile | |
David Meline | Chief Financial Officer | Profile | |
Francois Nader | Non-Executive Independent Director | Profile | |
Marcello Damiani | Chief Digital and Operational Excellence Officer | Profile | |
Shannon Klinger | Chief Sec | Profile | |
James Mock | Chief Officer | Profile | |
Lori Henderson | General Counsel, Company Secretary | Profile | |
Tal Zaks | Chief Medical Officer | Profile | |
John Reynders | Chief Officer | Profile | |
Paul Sagan | Non-Executive Independent Director | Profile | |
Lavina CFA | VP Relations | Profile | |
Melissa Moore | Chief Board | Profile | |
Elizabeth Tallett | Director | Profile | |
Stephen Hoge | President | Profile | |
Noubar Afeyan | Non-Executive Independent Chairman of the Board, Co-Founder | Profile | |
Stephen Berenson | Non-Executive Independent Director | Profile | |
Stephen MD | President | Profile | |
Robert Langer | Non-Executive Independent Director | Profile | |
Tracey Franklin | Chief Human Resource Officer | Profile | |
Ray Jordan | Chief Corporate Affairs Officer | Profile | |
Jerh Collins | Chief Officer | Profile | |
Juan Andres | Chief Technical Operations and Quality Officer | Profile | |
Israel Ruiz | Non-Executive Independent Director | Profile |
About Moderna Management Performance
The success or failure of an entity such as Moderna often depends on how effective the management is. Moderna management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moderna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moderna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1800 people.
Moderna Workforce Analysis
Traditionally, organizations such as Moderna use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moderna within its industry.Moderna Manpower Efficiency
Return on Moderna Manpower
Revenue Per Employee | 4.9M | |
Revenue Per Executive | 837.5M | |
Net Income Per Employee | 2.1M | |
Net Income Per Executive | 363.6M |
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |